AMTM vs TTEK

AMTM's deterministic health scores indicate moderate financial stability with a Piotroski F-Score of 4/9 (Stable range) but lack of Altman Z-Score limits distress risk assessment. The stock trades at a significant premium to its Graham Number ($10.6) and intrinsic value ($1.89), supported by strong revenue growth (77.4% YoY) and positive analyst sentiment (buy rating). However, weak profitability metrics, volatile earnings, and lack of cash flow transparency offset these positives. Recent price strength and high forward growth expectations are already priced in, limiting near-term upside.

TTEK demonstrates stable financial health with a Piotroski F-Score of 6/9 and a strong ROE of 19.92%. While the company possesses an exceptional track record of beating earnings estimates over 25 consecutive quarters, current revenue growth is a significant concern at -13.40% YoY. The stock trades at a steep premium to its Graham Number ($14.55) but remains below its growth-based intrinsic value ($39.23). Bearish technical trends and insider selling currently offset the positive analyst consensus and fundamental stability.